Acumen Pharmaceuticals ABOS 深 沪
等待开盘 12-18 09:30:00 美东时间
2.06
-0.040
-1.90%
华盛通- 最 高2.15
- 今 开2.13
- 成交量 8.02万股
- 最 低 2.02
- 昨 收 2.10
- 总市值 1.25亿
- 52周最高 2.46
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 0.8551
- 委 比 -20.00%
- 总股本 6057.34万
- 历史最高 26.98
- 量 比 0.58
- 振 幅 6.19%
- 历史最低 0.8551
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jim Lang Elected to Halozyme's Board of Directors
SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than ...
12-09 05:05
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
SAN DIEGO, Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction orderi...
12-05 02:26
Acumen And JCR Pharma Collaborative Study Shows Improved Brain Distribution of AβO-Targeting Antibodies
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD),
12-02 21:15
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
Acumen Pharmaceuticals announced the initiation of the open-label extension (OLE) phase of its Phase 2 ALTITUDE-AD trial for sabirnetug (ACU193), a therapy targeting soluble amyloid beta oligomers (AβOs) for early Alzheimer's disease (AD). All 542 participants who completed the 18-month placebo-controlled trial will receive sabirnetug intravenously every four weeks for 52 weeks. Sabirnetug, a humanized monoclonal antibody, demonstrated safety and...
11-17 13:00
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Preview: Acumen Pharmaceuticals's Earnings
Acumen Pharmaceuticals (NASDAQ:ABOS) is set to give its latest quarterly earnin...
11-12 01:13
Acumen Pharmaceuticals Appoints New Board Chairman
Acumen Pharmaceuticals ( ($ABOS) ) has shared an announcement. On November 10, ...
11-10 21:48
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing therapeutics targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer’s disease (AD), has announced that George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings over 30 years of experience in the biopharma industry, specializing in portfolio strategy, strategic collaborations, and M&A. His...
11-10 13:00
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announ...
11-07 21:30
